Chemotherapy plus targeted drug for organ preservation in rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of several chemotherapy drugs plus a targeted agent (bevacizumab) to shrink locally advanced rectal cancer, with the goal of avoiding surgery and keeping your rectum intact. It's designed for patients who wish to try this organ-preserving approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with locally advanced rectal cancer (stage II or III) that has not spread to distant organs.
- The tumor is located in the lower rectum (below 10 cm from the anal verge).
- You are willing to try a treatment plan aimed at avoiding surgery and preserving your rectum (organ preservation).
- You have not had any previous anticancer therapy for colorectal cancer.
- You are physically functional (able to care for yourself) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines chemotherapy, immunotherapy, and radiation before surgery for patients with middle or low rectal cancer. The goal is to shrink the tumor enough to avoid removing the anus, preserving bowel function.
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
This trial tests giving chemotherapy (mFOLFOXIRI) plus bevacizumab before surgery for rectal cancer that has higher-risk features. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial tests whether giving a combination of chemotherapy, radiation, and two newer drugs (an immunotherapy and an anti-angiogenesis drug) before surgery can improve outcomes for people with locally advanced rectal cancer. If you qualify, you would receive this treatment for a few months, and then have surgery.
This Phase 2 study tests whether a shorter course of radiation, combined with chemotherapy (CAPOX) and an immunotherapy drug (tislelizumab), can control middle and low rectal cancer. It may also help people who strongly want to keep their anus, if the cancer and overall health fit the study rules.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.